bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure and Table Legends from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Authors: Beuselinck Benoit , Job Sylvie , Becht Etienne , Karadimou Alexandra , Verkarre Virginie , Couchy Gabrielle , Giraldo Nicolas , Rioux-Leclercq Nathalie , Molinié Vincent , Sibony Mathilde , Elaidi Reza , Teghom Corinne , Patard Jean-Jacques , Méjean Arnaud , Fridman Wolf Herman , Sautès-Fridman Catherine , de Reyniès Aurélien , Oudard Stéphane , Zucman-Rossi Jessica
Published: April 2023

Supplementary Figure and Table Legends. Legends of all supplemental Figures and Tables
Supplementary Figure 4 from Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Authors: Ziemke Elizabeth K. , Dosch Joseph S. , Maust Joel D. , Shettigar Amrith , Sen Ananda , Welling Theodore H. , Hardiman Karin M. , Sebolt-Leopold Judith S.
Published: April 2023

Detection of Aberrant Methylation of p16 in CRC PDX Models. Analysis of genomic DNA by methylation-specific PCR.
Supplemental Figure S10 and Figure S11 from Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
Authors: Hoffman-Luca C. Gianna , Ziazadeh Daniel , McEachern Donna , Zhao Yujun , Sun Wei , Debussche Laurent , Wang Shaomeng
Published: April 2023

Supplemental Figure S10 and Figure S11. Activity of ABT-199 in RS4;11 sublines with acquired resistance to ABT-737 (Figure S10) or with with acquired resistance to SAR405838 (Figure S11).
Supplementary Figure 4 from c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
Authors: Liu Hongyan , Ai Jing , Shen Aijun , Chen Yi , Wang Xinyi , Peng Xia , Chen Hui , Shen Yanyan , Huang Min , Ding Jian , Geng Meiyu
Published: April 2023

c-Myc downregulation determines the response to FGFR inhibition of FGFR constitutively activated BaF3/TEL-FGFR cells.
Supplementary Figure 2 from c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
Authors: Liu Hongyan , Ai Jing , Shen Aijun , Chen Yi , Wang Xinyi , Peng Xia , Chen Hui , Shen Yanyan , Huang Min , Ding Jian , Geng Meiyu
Published: April 2023

c-Myc downregulation is essential for FGFR inhibition caused growth arrest in FGFR-addicted cells.
Supplementary Figure 1 from c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
Authors: Liu Hongyan , Ai Jing , Shen Aijun , Chen Yi , Wang Xinyi , Peng Xia , Chen Hui , Shen Yanyan , Huang Min , Ding Jian , Geng Meiyu
Published: April 2023

FGFR inhibition induces G1 phase cell cycle arrest in FGFR-addicted cancer cells.
Supplementary Table 1 from Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis
Authors: Bellini Angela , Bernard Virginie , Leroy Quentin , Rio Frio Thomas , Pierron Gaelle , Combaret Valérie , Lapouble Eve , Clement Nathalie , Rubie Herve , Thebaud Estelle , Chastagner Pascal , Defachelles Anne Sophie , Bergeron Christophe , Buchbinder Nimrod , Taque Sophie , Auvrignon Anne , Valteau-Couanet Dominique , Michon Jean , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun
Published: April 2023

Supplementary Table 1. Clinical and tumor genetic data of studied cohort of 276 NB patients
supplemental material-Figure S4 from Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer
Authors: Guo Xingjun , Zheng Lei , Jiang Jianxin , Zhao Yan , Wang Xin , Shen Ming , Zhu Feng , Tian Rui , Shi Chengjian , Xu Meng , Li Xu , Peng Feng , Zhang Hang , Feng Yechen , Xie Yu , Xu Xiaodong , Jia Wei , He Ruizhi , Xie Chencheng , Hu Jun , Ye Dawei , Wang Min , Qin Renyi
Published: April 2023

Figure S4: IL-18 promotes PC cell proliferation, invasion and metastasis.
Supplementary Table 1 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Authors: Di Stefano Anna Luisa , Fucci Alessandra , Frattini Veronique , Labussiere Marianne , Mokhtari Karima , Zoppoli Pietro , Marie Yannick , Bruno Aurelie , Boisselier Blandine , Giry Marine , Savatovsky Julien , Touat Mehdi , Belaid Hayat , Kamoun Aurelie , Idbaih Ahmed , Houillier Caroline , Luo Feng R. , Soria Jean-Charles , Tabernero Josep , Eoli Marica , Paterra Rosina , Yip Stephen , Petrecca Kevin , Chan Jennifer A. , Finocchiaro Gaetano , Lasorella Anna , Sanson Marc , Iavarone Antonio
Published: April 2023

Supplementary Table 1. Summary of FGFR-TACC fusion transcripts identified in all cancer types.
Supplementary Figure 4 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Authors: Di Stefano Anna Luisa , Fucci Alessandra , Frattini Veronique , Labussiere Marianne , Mokhtari Karima , Zoppoli Pietro , Marie Yannick , Bruno Aurelie , Boisselier Blandine , Giry Marine , Savatovsky Julien , Touat Mehdi , Belaid Hayat , Kamoun Aurelie , Idbaih Ahmed , Houillier Caroline , Luo Feng R. , Soria Jean-Charles , Tabernero Josep , Eoli Marica , Paterra Rosina , Yip Stephen , Petrecca Kevin , Chan Jennifer A. , Finocchiaro Gaetano , Lasorella Anna , Sanson Marc , Iavarone Antonio
Published: April 2023

Supplementary Figure 4. The FGFR3-TACC3 fusion gene and protein are retained in recurrent GBM.
Supplementary figure 6 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Authors: van Gool Inge C. , Eggink Florine A. , Freeman-Mills Luke , Stelloo Ellen , Marchi Emanuele , de Bruyn Marco , Palles Claire , Nout Remi A. , de Kroon Cor D. , Osse Elisabeth M. , Klenerman Paul , Creutzberg Carien L. , Tomlinson Ian P.M. , Smit Vincent T.H.B.M. , Nijman Hans W. , Bosse Tjalling , Church David N.
Published: April 2023

Supplementary figure 6. T cell exhaustion markers according to tumor CD8A expression and EC molecular subtype
Supplementary Figures S1-6 from Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma
Authors: Agelopoulos Konstantin , Richter Günther H.S. , Schmidt Eva , Dirksen Uta , von Heyking Kristina , Moser Benjamin , Klein Hans-Ulrich , Kontny Udo , Dugas Martin , Poos Kathrin , Korsching Eberhard , Buch Thorsten , Weckesser Matthias , Schulze Isabell , Besoke Regina , Witten Anika , Stoll Monika , Köhler Gabriele , Hartmann Wolfgang , Wardelmann Eva , Rossig Claudia , Baumhoer Daniel , Jürgens Heribert , Burdach Stefan , Berdel Wolfgang E. , Müller-Tidow Carsten
Published: April 2023

Supplementary Figures S1-6. Supplementary Fig S1: Combined patient characteristics and subjected methods Supplementary Fig. S2 A: ROC curves were constructed by using the somatic scores from the sequenced genotypes. Supplementary Fig. S3: Circos plots of representative Ewing sarcomas. Supplementary Fig. S4: Sanger sequencing results confirmed (A) somatic inactivating mutations of the STAG2 gene (positions according to RefSeq NG 033796.2) and (B) the activating N546 mutation of FGFR1. Supplementary Fig. S5: FGFR-1 expression in Ewing Sarcomas by means of real time RT PCR (A, normalized to FGFR-1 expression in VH-64). (B) Array-based analysis of FGFR1 expression in ES compared to normal tissue (NBA; SI Materials and Methods). (C) Knock-down by means of lentiviral transduced FGFR1.shRNA effectively reduced FGFR1 mRNA expression by 70 % or more in Ewing sarcoma cell lines as compared to scrambled shRNA. (D) Knockdown was confirmed on the protein level by means of western blotting. Supplementary Fig. S6: Amplification of the FGFR-1 gene (A) as well as gene expression (B) are associated with a trend towards inferior survival in patients with ES. (C) Treatment with Ponatinib inhibited growth of ES cell lines significantly. (D) FGFR1 tyrosine kinase inhibitor therapy in a patient with relapsed Ewing sarcoma.
Supplementary figure 3 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Authors: van Gool Inge C. , Eggink Florine A. , Freeman-Mills Luke , Stelloo Ellen , Marchi Emanuele , de Bruyn Marco , Palles Claire , Nout Remi A. , de Kroon Cor D. , Osse Elisabeth M. , Klenerman Paul , Creutzberg Carien L. , Tomlinson Ian P.M. , Smit Vincent T.H.B.M. , Nijman Hans W. , Bosse Tjalling , Church David N.
Published: April 2023

Supplementary figure 3. Number of TIA-1+ cytolytic T cells according to molecular subtype
List of pathways analyzed for GSEA from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
Authors: Poulain Stéphanie , Roumier Christophe , Venet-Caillault Aurélie , Figeac Martin , Herbaux Charles , Marot Guillemette , Doye Emmanuelle , Bertrand Elisabeth , Geffroy Sandrine , Lepretre Frédéric , Nibourel Olivier , Decambron Audrey , Boyle Eileen Mary , Renneville Aline , Tricot Sabine , Daudignon Agnès , Quesnel Bruno , Duthilleul Patrick , Preudhomme Claude , Leleu Xavier
Published: April 2023

List of pathways analyzed for GSEA
Supplementary Figure S2 from Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents
Authors: Amaral Ana Teresa , Garofalo Cecilia , Frapolli Roberta , Manara Maria Cristina , Mancarella Caterina , Uboldi Sarah , Giandomenico Silvana Di , Ordóñez Jose Luis , Sevillano Victoria , Malaguarnera Roberta , Picci Piero , Hassan A. Bass , Alava Enrique De , D'Incalci Maurizio , Scotlandi Katia
Published: April 2023

Supplementary Figure S2. Time course of EWS-FLI1 association with IGF-1R promoter and EWS-FLI1 occupacy on IGF-1 promoter.
Supplementary Figure S1 from Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents
Authors: Amaral Ana Teresa , Garofalo Cecilia , Frapolli Roberta , Manara Maria Cristina , Mancarella Caterina , Uboldi Sarah , Giandomenico Silvana Di , Ordóñez Jose Luis , Sevillano Victoria , Malaguarnera Roberta , Picci Piero , Hassan A. Bass , Alava Enrique De , D'Incalci Maurizio , Scotlandi Katia
Published: April 2023

Supplementary Figure S1. Antitumor activity of trabectedin and doxorubicin in EWS xenografts.
Supplementary Table S5 from LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival
Authors: Torres Sofía , Garcia-Palmero Irene , Herrera Mercedes , Bartolomé Rubén A. , Peña Cristina , Fernandez-Aceñero M. Jesús , Padilla Guillermo , Peláez-García Alberto , Lopez-Lucendo María , Rodriguez-Merlo Rufo , de Herreros Antonio García , Bonilla Félix , Casal J. Ignacio
Published: April 2023

Supplementary Table S5. Markers CAFs expressed preferentially in tumoral stroma of colorectal cancer using inmunohistochemistry of Human Protein Atlas
Supplementary Figure S3B from Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Authors: Janni Wolfgang J. , Rack Brigitte , Terstappen Leon W.M.M. , Pierga Jean-Yves , Taran Florin-Andrei , Fehm Tanja , Hall Carolyn , de Groot Marco R. , Bidard François-Clement , Friedl Thomas W.P. , Fasching Peter A. , Brucker Sara Y. , Pantel Klaus , Lucci Anthony
Published: April 2023

Figure S3. Kaplan-Meier plots of overall survival according to the presence of circulating tumor cells at the time of primary breast cancer diagnosis. Panel A shows the predefined low-risk (T1/N0) patient subgroup, and Panel B shows the high-risk (T234/N123) patient subgroup.
Supplementary Table S2. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Authors: Jenkinson Claire , Elliott Victoria L. , Evans Anthony , Oldfield Lucy , Jenkins Rosalind E. , O'Brien Darragh P. , Apostolidou Sophia , Gentry-Maharaj Aleksandra , Fourkala Evangelia-O , Jacobs Ian J. , Menon Usha , Cox Trevor , Campbell Fiona , Pereira Stephen P. , Tuveson David A. , Park B. Kevin , Greenhalf William , Sutton Robert , Timms John F. , Neoptolemos John P. , Costello Eithne
Published: April 2023

Peptides and their fragment ions used in MRM assays for TSP-1.
Supplementary Table S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Authors: Jenkinson Claire , Elliott Victoria L. , Evans Anthony , Oldfield Lucy , Jenkins Rosalind E. , O'Brien Darragh P. , Apostolidou Sophia , Gentry-Maharaj Aleksandra , Fourkala Evangelia-O , Jacobs Ian J. , Menon Usha , Cox Trevor , Campbell Fiona , Pereira Stephen P. , Tuveson David A. , Park B. Kevin , Greenhalf William , Sutton Robert , Timms John F. , Neoptolemos John P. , Costello Eithne
Published: April 2023

Patient Characteristics of iTRAQ sample pools.
Supplementary Figure S1. from Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus
Authors: Jenkinson Claire , Elliott Victoria L. , Evans Anthony , Oldfield Lucy , Jenkins Rosalind E. , O'Brien Darragh P. , Apostolidou Sophia , Gentry-Maharaj Aleksandra , Fourkala Evangelia-O , Jacobs Ian J. , Menon Usha , Cox Trevor , Campbell Fiona , Pereira Stephen P. , Tuveson David A. , Park B. Kevin , Greenhalf William , Sutton Robert , Timms John F. , Neoptolemos John P. , Costello Eithne
Published: April 2023

(A) Peptides unique to TSP-1 (in red) were used to quantify the protein using multiple reaction monitoring (MRM). (B) Detection of TSP-1 by western analysis in UKCTOCS and PBRU samples. Human Foreskin Fibroblast (HFF) cells treated with TSP-1-targeting and control siRNAs were used to validate the antibody.
Supplementary Table S1 from Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma
Authors: Ekmekcioglu Suhendan , Davies Michael A. , Tanese Keiji , Roszik Jason , Shin-Sim Myung , Bassett Roland L. , Milton Denái R. , Woodman Scott E. , Prieto Victor G. , Gershenwald Jeffrey E. , Morton Donald L. , Hoon Dave S. , Grimm Elizabeth A.
Published: April 2023

This file contains distribution of the markers in discovery and validation set samples
Supplemental Tables S1-6 from Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy
Authors: Komatsu Masaaki , Wheeler Heather E. , Chung Suyoun , Low Siew-Kee , Wing Claudia , Delaney Shannon M. , Gorsic Lidija K. , Takahashi Atsushi , Kubo Michiaki , Kroetz Deanna L. , Zhang Wei , Nakamura Yusuke , Dolan M. Eileen
Published: April 2023

Supplemental Tables S1-6. Table S1. Clinical characteristics of cancer patients with paclitaxel-induced sensory peripheral neuropathy ({greater than or equal to} grade 2) as cases and no neuropathy as controls. Table S2. GWAS of SNPs located in or near AIPL1 gene Table S3. Overlap genes associated with Asian paclitaxel-induced LCL cytotoxicity (P < 0.05) and Asian patient sensory peripheral neuropathy (P < 0.05). Table S4. Overlap genes associated with paclitaxel-induced LCL cytotoxicity (P < 0.05) and European patient sensory peripheral neuropathy (P < 0.05). Table S5. Overlap genes associated with Asian patient sensory peripheral neuropathy (P < 0.05) and European patient sensory peripheral neuropathy (P < 0.05). Table S6. RNA-Seq gene expression levels and literature evidence of overlap genes associated with Asian paclitaxel-induced LCL cytotoxicity (P < 0.05) and Asian patient sensory peripheral neuropathy (P < 0.05).
Supplemantary Figure S3 from Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma
Authors: Ekmekcioglu Suhendan , Davies Michael A. , Tanese Keiji , Roszik Jason , Shin-Sim Myung , Bassett Roland L. , Milton Denái R. , Woodman Scott E. , Prieto Victor G. , Gershenwald Jeffrey E. , Morton Donald L. , Hoon Dave S. , Grimm Elizabeth A.
Published: April 2023

Clinical outcomes by combined markers of CD74 and MIF in tumor cells in stage III melanoma patients in discovery (A) and validation (B) datasets. Kaplan-Meier analyses are shown for OS and RFS for their expression by percentage of staining.
Supplementary Table 3 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
Authors: Adjei Alex A. , Richards Donald A. , El-Khoueiry Anthony , Braiteh Fadi , Becerra Carlos H.R. , Stephenson Joe J. , Hezel Aram F. , Sherman Morris , Garbo Lawrence , Leffingwell Diane P. , Iverson Cory , Miner Jeffrey N. , Shen Zancong , Yeh Li-Tain , Gunawan Sonny , Wilson David M. , Manhard Kimberly J. , Rajagopalan Prabhu , Krissel Heiko , Clendeninn Neil J.
Published: April 2023

Overview of dose-limiting toxicities and adverse events leading to discontinuation and relationship to study treatment
Supplementary Figure 2 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
Authors: Adjei Alex A. , Richards Donald A. , El-Khoueiry Anthony , Braiteh Fadi , Becerra Carlos H.R. , Stephenson Joe J. , Hezel Aram F. , Sherman Morris , Garbo Lawrence , Leffingwell Diane P. , Iverson Cory , Miner Jeffrey N. , Shen Zancong , Yeh Li-Tain , Gunawan Sonny , Wilson David M. , Manhard Kimberly J. , Rajagopalan Prabhu , Krissel Heiko , Clendeninn Neil J.
Published: April 2023

CTC enumeration and pERK analysis in course 1
Supplementary tables and figure legends from Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
Authors: Niemann Carsten U. , Herman Sarah E.M. , Maric Irina , Gomez-Rodriguez Julio , Biancotto Angelique , Chang Betty Y. , Martyr Sabrina , Stetler-Stevenson Maryalice , Yuan Constance M. , Calvo Katherine R. , Braylan Raul C. , Valdez Janet , Lee Yuh Shan , Wong Deanna H. , Jones Jade , Sun Clare , Marti Gerald E. , Farooqui Mohammed Z.H. , Wiestner Adrian
Published: April 2023

Supplementary Table S1: Evaluation of serum cytokine levels on ibrutinib Supplementary Table S2: Evaluation of chemoattractant levels in bone marrow supernatant on ibrutinib supplementary figure legends for supplementary figures S1-S5
Supplemental Data 10 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
Authors: Lambertz Irina , Kumps Candy , Claeys Shana , Lindner Sven , Beckers Anneleen , Janssens Els , Carter Daniel R. , Cazes Alex , Cheung Belamy B. , De Mariano Marilena , De Bondt An , De Brouwer Sara , Delattre Olivier , Gibbons Jay , Janoueix-Lerosey Isabelle , Laureys Geneviève , Liang Chris , Marchall Glenn M. , Porcu Michael , Takita Junko , Trujillo David Camacho , Van Den Wyngaert Ilse , Van Roy Nadine , Van Goethem Alan , Van Maerken Tom , Zabrocki Piotr , Cools Jan , Schulte Johannes H. , Vialard Jorge , Speleman Frank , De Preter Katleen
Published: April 2023

Supplemental data 10: Results of gene ontology analysis performed on the 77 ALK signature genes
Supplementary Methods, Figures 1-2, Tables 1-3 from Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy
Authors: Cohen Daniel N. , Lawson Steven K. , Shaver Aaron C. , Du Liping , Nguyen Harrison P. , He Qin , Johnson Douglas B. , Lumbang Wilfred A. , Moody Brent R. , Prescott James L. , Chandra Pranil K. , Boyd Alan S. , Zwerner Jeffrey P. , Robbins Jason B. , Tyring Stephen K. , Rady Peter L. , Chappell James D. , Shyr Yu , Infante Jeffrey R. , Sosman Jeffrey A.
Published: April 2023

Supplementary Methods, Figures 1-2, Tables 1-3. Phylogenetic analysis, novel HPV alignment and NGS gene panel. Figure S1 - β-genus HPV38, HPV17 and HPV111 are most frequently found in BRAFi-cSCC; Figure S2: Protein and nucleic acid sequence alignments of putative novel HPV genotypes; Table S1: HPV L1 sequences were obtained from NCBI for alignment and relatedness analysis; Table S2 Human Papillomavirus Taxonomy; Table S3: Ion Torrent Ampliseq panel targets.
Supplemental Figure S3. Correlogram of the MV score and 22 gene modules in four datasets from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Authors: Tobin Nicholas P. , Wennmalm Kristian , Lindström Linda S. , Foukakis Theodoros , He Liqun , Genové Guillem , Östman Arne , Landberg Göran , Betsholtz Christer , Bergh Jonas
Published: April 2023

Correlations between the MV score and 22 gene modules in (A) Uppsala dataset, (B) Stockholm dataset, (C) NKI dataset and (D) Rotterdam dataset.
Supplemental Figure S1. MV score ROC cutoffs and Kaplan-Meier survival curves for distant metastasis-free survival, split by treatment subgroups from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Authors: Tobin Nicholas P. , Wennmalm Kristian , Lindström Linda S. , Foukakis Theodoros , He Liqun , Genové Guillem , Östman Arne , Landberg Göran , Betsholtz Christer , Bergh Jonas
Published: April 2023

(A) ROC and (B) Kaplan-Meier analysis of our training dataset in patient subgroups (i) All, (ii) Untreated, (iii) Untreated ER positive and (iv) Endocrine treated patients.
Supplemental Tables 1-2 from ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI
Authors: Gerstner Elizabeth R. , Zhang Zheng , Fink James R. , Muzi Mark , Hanna Lucy , Greco Erin , Prah Melissa , Schmainda Kathleen M. , Mintz Akiva , Kostakoglu Lale , Eikman Edward A. , Ellingson Benjamin M. , Ratai Eva-Maria , Sorensen A. Gregory , Barboriak Daniel P. , Mankoff David A.
Published: April 2023

Supplemental Table 1: Participating centers that enrolled patients; Supplemental Table 2: Serial FMISO PET Imaging.
Supplementary Figure 3 from PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Authors: Incio Joao , Tam Josh , Rahbari Nuh N. , Suboj Priya , McManus Dan T. , Chin Shan M. , Vardam Trupti D. , Batista Ana , Babykutty Suboj , Jung Keehoon , Khachatryan Anna , Hato Tai , Ligibel Jennifer A. , Krop Ian E. , Puchner Stefan B. , Schlett Christopher L. , Hoffmman Udo , Ancukiewicz Marek , Shibuya Masabumi , Carmeliet Peter , Soares Raquel , Duda Dan G. , Jain Rakesh K. , Fukumura Dai
Published: April 2023

Supplementary Figure 3 - Expression of VEGFR-1 and IL-1ÃƒÅ¸ in TAMs in PAN02 tumors.
Supplementary Figure 6 from NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma
Authors: Lai Robin Kit-Ho , Xu Iris Ming-Jing , Chiu David Kung-Chun , Tse Aki Pui-Wah , Wei Larry Lai , Law Cheuk-Ting , Lee Derek , Wong Chun-Ming , Wong Maria Pik , Ng Irene Oi-Lin , Wong Carmen Chak-Lui
Published: April 2023

Figure S6. Knockdown of NDUFA4L2 induces ROS-mediated apoptosis and suppresses cell proliferation.
Supplementary Figure 5 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
Authors: Ma Zhifeng , Li Wen , Yoshiya Shinichi , Xu Yunfeng , Hata Masaki , El-Darawish Yosif , Markova Tzvetanka , Yamanishi Kyosuke , Yamanishi Hiromichi , Tahara Hideaki , Tanaka Yoshimasa , Okamura Haruki
Published: April 2023

Phenotypic analyses of PECs depleted with NK lineage cells
Supplementary Figure 3 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
Authors: Ma Zhifeng , Li Wen , Yoshiya Shinichi , Xu Yunfeng , Hata Masaki , El-Darawish Yosif , Markova Tzvetanka , Yamanishi Kyosuke , Yamanishi Hiromichi , Tahara Hideaki , Tanaka Yoshimasa , Okamura Haruki
Published: April 2023

Cytokine production by PECs from pre-implanted mice receiving immune checkpoint blockade and/or IL-18
Supplementary Figure 1 from NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma
Authors: Lai Robin Kit-Ho , Xu Iris Ming-Jing , Chiu David Kung-Chun , Tse Aki Pui-Wah , Wei Larry Lai , Law Cheuk-Ting , Lee Derek , Wong Chun-Ming , Wong Maria Pik , Ng Irene Oi-Lin , Wong Carmen Chak-Lui
Published: April 2023

Figure S1: NDUFA4L2 is over-expressed in human solid cancers.
Supplementary Table S3 from Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Authors: Arena Sabrina , Bellosillo Beatriz , Siravegna Giulia , Martínez Alejandro , Cañadas Israel , Lazzari Luca , Ferruz Noelia , Russo Mariangela , Misale Sandra , González Iria , Iglesias Mar , Gavilan Elena , Corti Giorgio , Hobor Sebastijan , Crisafulli Giovanni , Salido Marta , Sánchez Juan , Dalmases Alba , Bellmunt Joaquim , De Fabritiis Gianni , Rovira Ana , Di Nicolantonio Federica , Albanell Joan , Bardelli Alberto , Montagut Clara
Published: April 2023

Supplementary Table S3. Prevalence of EGFR mutations in resistant cell lines.
Supplementary Figure S2 from Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Authors: Arena Sabrina , Bellosillo Beatriz , Siravegna Giulia , Martínez Alejandro , Cañadas Israel , Lazzari Luca , Ferruz Noelia , Russo Mariangela , Misale Sandra , González Iria , Iglesias Mar , Gavilan Elena , Corti Giorgio , Hobor Sebastijan , Crisafulli Giovanni , Salido Marta , Sánchez Juan , Dalmases Alba , Bellmunt Joaquim , De Fabritiis Gianni , Rovira Ana , Di Nicolantonio Federica , Albanell Joan , Bardelli Alberto , Montagut Clara
Published: April 2023

Supplementary Figure S2. Comparison of parental and cetuximab resistant cell lines.
Supplementary Figure S1 from Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Authors: Arena Sabrina , Bellosillo Beatriz , Siravegna Giulia , Martínez Alejandro , Cañadas Israel , Lazzari Luca , Ferruz Noelia , Russo Mariangela , Misale Sandra , González Iria , Iglesias Mar , Gavilan Elena , Corti Giorgio , Hobor Sebastijan , Crisafulli Giovanni , Salido Marta , Sánchez Juan , Dalmases Alba , Bellmunt Joaquim , De Fabritiis Gianni , Rovira Ana , Di Nicolantonio Federica , Albanell Joan , Bardelli Alberto , Montagut Clara
Published: April 2023

Supplementary Figure S1. Nucleotide sequence of the EGFR gene in tumor specimen.
Supplemental figure 3 from A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
Authors: Ko Andrew H. , Bekaii-Saab Tanios , Van Ziffle Jessica , Mirzoeva Olga M. , Joseph Nancy M. , Talasaz AmirAli , Kuhn Peter , Tempero Margaret A. , Collisson Eric A. , Kelley R. Kate , Venook Alan P. , Dito Elizabeth , Ong Anna , Ziyeh Sharvina , Courtin Ryan , Linetskaya Regina , Tahiri Sanaa , Korn W. Michael
Published: April 2023

Supplemental figure 3. Mutation frequencies in pre-and on-treatment plasma samples as determined by next-generation sequencing of cfDNA using the Guardant360 assay.
Supplementary Tables 1-2, Supplementary Figures 1-6 from Dysfunctional Antibodies in the Tumor Microenvironment Associate with Impaired Anticancer Immunity
Authors: Zhang Ningyan , Deng Hui , Fan Xuejun , Gonzalez Anneliese , Zhang Songlin , Brezski Randall J. , Choi Byung-Kwon , Rycyzyn Michael , Strohl William , Jordan Robert , An Zhiqiang
Published: April 2023

Supplementary Tables 1-2, Supplementary Figures 1-6. Supplemental table 1. Patient clinical information; Supplemental table 2 Patient clinical information; Supplemental Figure 1. Standard curves developed for calculation of IgG subclasses; Supplemental Figure 2. Profiles of IgG subclasses in tumor and plasma samples; Supplemental Figure 3. IgG2 subclass showed much lower binding to Fc gamma receptors than the IgG1 counterpart; Supplemental Figure 4. Elevated scIgGs in tumor tissues were associated with reduced interactions with Fc gamma receptors; Supplemental Figure 5. Breast tumor tissues had significantly higher sum total of MMPs (MMP-1, 2 , 3, 8, 9, 10, 13) than in normal breast tissues; Supplemental Figure 6. There was no clear correlation between scIgG levels in tumor tissues and patient cancer grades or stages at the time of diagnosis
supplementary table 1 from Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake
Authors: Trani Daniela , Yaromina Ala , Dubois Ludwig , Granzier Marlies , Peeters Sarah G.J.A. , Biemans Rianne , Nalbantov Georgi , Lieuwes Natasja , Reniers Brigitte , Troost Esther E.G.C. , Verhaegen Frank , Lambin Philippe
Published: April 2023

Comparison between average CT planned and CBCT recalculated dose metrics (Gy) for the target structures. All doses are reported as means [standard deviation] in units of Gy
Supplementary Figure 4 from Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer
Authors: Abdel-Fatah Tarek M. , Ball Graham , Lee Andrew H.S. , Pinder Sarah , MacMilan R. Douglas , Cornford Eleanor , Moseley Paul M. , Silverman Rafael , Price James , Latham Bruce , Palmer David , Chan Arlene , Ellis Ian O. , Chan Stephen Y.T.
Published: April 2023

Supplementary Figure 4. Multivariable Cox proportional hazards regression analyses for disease free survival (DFS; left panel) and corresponding forest plots (Right panel).
Supplementary Figure 4 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
Authors: Pham Christina D. , Flores Catherine , Yang Changlin , Pinheiro Elaine M. , Yearley Jennifer H. , Sayour Elias J. , Pei Yanxin , Moore Colin , McLendon Roger E. , Huang Jianping , Sampson John H. , Wechsler-Reya Robert , Mitchell Duane A.
Published: April 2023

T cell infiltration within the NSC MB tumor microenvironment does not correlate with DC infiltration.
Supplementary Table S1 from Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
Authors: Herman Sarah E.M. , Mustafa Rashida Z. , Jones Jade , Wong Deanna H. , Farooqui Mohammed , Wiestner Adrian
Published: April 2023

Supplementary Table S1: Breakdown of patients by experiment
Supplementary Table 1 from Topical Application of a Mucoadhesive Freeze-Dried Black Raspberry Gel Induces Clinical and Histologic Regression and Reduces Loss of Heterozygosity Events in Premalignant Oral Intraepithelial Lesions: Results from a Multicentered, Placebo-Controlled Clinical Trial
Authors: Mallery Susan R. , Tong Meng , Shumway Brian S. , Curran Alice E. , Larsen Peter E. , Ness Gregory M. , Kennedy Kelly S. , Blakey George H. , Kushner George M. , Vickers Aaron M. , Han Brian , Pei Ping , Stoner Gary D.
Published: April 2023

PDF file - 59KB, Function of proteins evaluated by immunoblotting.
Supplementary Figures 1 - 3, Table 1 from Inhibition of NANOG/NANOGP8 Downregulates MCL-1 in Colorectal Cancer Cells and Enhances the Therapeutic Efficacy of BH3 Mimetics
Authors: Mattoo Abid R. , Zhang Jingyu , Espinoza Luis A. , Jessup J. Milburn
Published: April 2023

Figure S1: Dose response curve of CX-1 cells treated with LVshNp81 in combination of increasing concentrations of ABT-737. Supplementary Table 1 : IC50 values of CRC cell lines treated with ABT-737 and ABT-199. Figure S2:Lentiviral Delivered (LV) shRNA to NANOG or NANOGP8 decreases the phosphorylation of AKT and decreases MCL-1 levels. Figure S3: Re-plating assay of CRC cells treated with LV shRNA against NANOG and NANOGP8 and ABT-737.
Supplementary text S1 from Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer
Authors: Lee Se-Ra , Roh Yun-Gil , Kim Seon-Kyu , Lee Ju-Seog , Seol So-Young , Lee Hyun-Hee , Kim Won-Tae , Kim Wun-Jae , Heo Jeonghoon , Cha Hee-Jae , Kang Tae-Hong , Chung Jin Woong , Chu In-Sun , Leem Sun-Hee
Published: April 2023

Supplementary Text S1. Comparison of other signatures with the three-gene signature
Supplementary Materials and Methods, Supplementary Figure Legend, Supplementary Table 1 from The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy
Authors: Zsiros Emese , Duttagupta Priyanka , Dangaj Denarda , Li Hongzhe , Frank Renee , Garrabrant Thomas , Hagemann Ian S. , Levine Bruce L. , June Carl H. , Zhang Lin , Wang Ena , Marincola Francesco M. , Bedognetti Davide , Powell Daniel J. , Tanyi Janos , Feldman Michael D. , Kandalaft Lana E. , Coukos George
Published: April 2023

Supplementary Materials and Methods, Supplementary Figure Legend, Supplementary Table 1. Supplementary Table 1: Cell line origin and characteristics
Supplementary Figures S1-8 from Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer
Authors: Lee Se-Ra , Roh Yun-Gil , Kim Seon-Kyu , Lee Ju-Seog , Seol So-Young , Lee Hyun-Hee , Kim Won-Tae , Kim Wun-Jae , Heo Jeonghoon , Cha Hee-Jae , Kang Tae-Hong , Chung Jin Woong , Chu In-Sun , Leem Sun-Hee
Published: April 2023

Supplementary Figures S1 - S8 Supplementary Figure S1. Validation of the three gene signature (E2F1, EZH2 and SUZ12) in independent non-muscle-invasive bladder cancer (NMIBC) patient cohorts. Supplementary Figure S2. Comparison with other signatures and validation of the signature in an independent cohort. Supplementary Figure S3. Classification into two subgroups of bladder cancer cell lines according to expression levels and invasive ability. Supplementary Figure S4. Overexpression of E2F1, EZH2, and SUZ12 promoted invasion and migration in UC5 NMIBC cells. Supplementary Figure S5. Decreased expression of E2F1, EZH2, and SUZ12 regulated invasion and migration in 5637 MIBC cells. Supplementary Figure S6. Characterization of shE2F1-KD, shEZH2-KD, and shSUZ12-KD stably expressing cells. Figure S7. Cancer stem cell signatures were analyzed under anti-cancer drug treated condition. Figure S8. Cell viability of UC5 cells under cisplatin treatment.
Supplementary Figures from ESR1 Methylation: A Liquid Biopsy–Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment
Authors: Mastoraki Sophia , Strati Areti , Tzanikou Eleni , Chimonidou Maria , Politaki Eleni , Voutsina Alexandra , Psyrri Amanda , Georgoulias Vassilis , Lianidou Evi
Published: April 2023

Supplementary Figure 1A Supplementary Figure 1B Supplementary Figure 2A Supplementary Figure 2B
Supplemental Figure 1 from Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
Authors: Sarantopoulos John , Shapiro Geoffrey I. , Cohen Roger B. , Clark Jeffrey W. , Kauh John S. , Weiss Glen J. , Cleary James M. , Mahalingam Devalingam , Pickard Michael D. , Faessel Hélène M. , Berger Allison J. , Burke Kristine , Mulligan George , Dezube Bruce J. , Harvey R. Donald
Published: April 2023

Individual dose-normalized exposures of pevonedistat (as assessed by Cmax and AUC24) obtained on Day 1 and Day 5 for schedule B (with dexamethasone) and schedule C (without dexamethasone).
Supplemental Figure S6 from 18F-FAZA PET Imaging Response Tracks the Reoxygenation of Tumors in Mice upon Treatment with the Mitochondrial Complex I Inhibitor BAY 87-2243
Authors: Chang Edwin , Liu Hongguang , Unterschemmann Kerstin , Ellinghaus Peter , Liu Shuanglong , Gekeler Volker , Cheng Zhen , Berndorff Dietmar , Gambhir Sanjiv S.
Published: April 2023

Supplemental Figure S6. Bar graphs showing effect of BAY 87-2243 on RT-PCR expression profiles for (A) PDK-1, (B) GLUT-1, (C) GLUT-3 and (D) HK-2
Supplemental Figure S5 from 18F-FAZA PET Imaging Response Tracks the Reoxygenation of Tumors in Mice upon Treatment with the Mitochondrial Complex I Inhibitor BAY 87-2243
Authors: Chang Edwin , Liu Hongguang , Unterschemmann Kerstin , Ellinghaus Peter , Liu Shuanglong , Gekeler Volker , Cheng Zhen , Berndorff Dietmar , Gambhir Sanjiv S.
Published: April 2023

Supplemental Figure S5. Bar graphs showing effect of BAY 87-2243 on RT-PCR expression profiles for (A) SLC16A, (B) ITGB1, (C) IGF-2 and (D) TK-1
Supplemental Figure S1 from 18F-FAZA PET Imaging Response Tracks the Reoxygenation of Tumors in Mice upon Treatment with the Mitochondrial Complex I Inhibitor BAY 87-2243
Authors: Chang Edwin , Liu Hongguang , Unterschemmann Kerstin , Ellinghaus Peter , Liu Shuanglong , Gekeler Volker , Cheng Zhen , Berndorff Dietmar , Gambhir Sanjiv S.
Published: April 2023

Supplemental Figure S1. Graph showing no effect of BAY 87-2243 on weight of nude mice carrying either H460 or PC3 tumor xenografts. Similar results for mice with 786-O xenografts (data not shown).
List of legend for supplementary files from 18F-FAZA PET Imaging Response Tracks the Reoxygenation of Tumors in Mice upon Treatment with the Mitochondrial Complex I Inhibitor BAY 87-2243
Authors: Chang Edwin , Liu Hongguang , Unterschemmann Kerstin , Ellinghaus Peter , Liu Shuanglong , Gekeler Volker , Cheng Zhen , Berndorff Dietmar , Gambhir Sanjiv S.
Published: April 2023

List of legend for supplementary files. Description list for supplementary files
Supplemental figure 3 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
Authors: van der Sluis Tetje C. , van Duikeren Suzanne , Huppelschoten Suzanna , Jordanova Ekaterina S. , Beyranvand Nejad Elham , Sloots Arjen , Boon Louis , Smit Vincent T.H.B.M. , Welters Marij J.P. , Ossendorp Ferry , van de Water Bob , Arens Ramon , van der Burg Sjoerd H. , Melief Cornelis J.M.
Published: April 2023

Supplemental figure 3) Synergistic effects between cisplatin and peptide vaccination preserved with other treatment protocol
Supplementary Figure 5 from Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice
Authors: Kim Sun-Jin , Lee Ho Jeong , Kim Mark Seungwook , Choi Hyun Jin , He Junqin , Wu Qiuyu , Aldape Kenneth , Weinberg Jeffrey S. , Yung W.K. Alfred , Conrad Charles A. , Langley Robert R. , Lehembre François , Regenass Urs , Fidler Isaiah J.
Published: April 2023

Supplementary Figure 5. MGMT promoter methylation in orthotopically implanted LN- 229, LN-229Res, and D54Res glioblastomas.
Supplementary Figure 2 from Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice
Authors: Kim Sun-Jin , Lee Ho Jeong , Kim Mark Seungwook , Choi Hyun Jin , He Junqin , Wu Qiuyu , Aldape Kenneth , Weinberg Jeffrey S. , Yung W.K. Alfred , Conrad Charles A. , Langley Robert R. , Lehembre François , Regenass Urs , Fidler Isaiah J.
Published: April 2023

Supplementary Figure 2. Combination therapy with macitentan plus TMZ eradicates experimental glioblastomas.
Supplemental Figure 1 from An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
Authors: Bikos Vasilis , Karypidou Maria , Stalika Evangelia , Baliakas Panagiotis , Xochelli Aliki , Sutton Lesley-Ann , Papadopoulos George , Agathangelidis Andreas , Papadopoulou Evdoxia , Davis Zadie , Algara Patricia , Kanellis George , Traverse-Glehen Alexandra , Mollejo Manuela , Anagnostopoulos Achilles , Ponzoni Maurilio , Gonzalez David , Pospisilova Sarka , Matutes Estella , Piris Miguel Angel , Papadaki Theodora , Ghia Paolo , Rosenquist Richard , Oscier David , Darzentas Nikos , Tzovaras Dimitrios , Belessi Chrysoula , Hadzidimitriou Anastasia , Stamatopoulos Kostas
Published: April 2023

Network of the aligned IGVH1-2*04 CDR3 sub-regions, depicting the emerging patterns
Supplementary Tables 1-3, Figures 1-6 from Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non–Small Cell Lung Cancer Patients (SAKK 19/05 trial)
Authors: Franzini Anca , Baty Florent , Macovei Ina I. , Dürr Oliver , Droege Cornelia , Betticher Daniel , Grigoriu Bogdan D. , Klingbiel Dirk , Zappa Francesco , Brutsche Martin H.
Published: April 2023

Supplementary Tables 1-3, Figures 1-6. Supplementary Table 1: Statistical analysis of differences between the study group and the remaining group of patients for several variables. Supplementary Table 2: Primers used for the RT-qPCR assays. Supplementary Table 3: Leave-one-out cross-validation of the angiogenesis-associated and hypoxia gene signatures. Supplementary Figure 1: Average gene expression levels for the top 10-ranked angiogenesis signature calculated based on the microarray data (N = 42 patients) for low (Cluster A1), high (Cluster A2) and medium (Cluster A3) risk patients. Supplementary Figure 2: Average gene expression levels for the top 10-ranked hypoxia response signature calculated based on the microarray data (N = 42 patients). Supplementary Figure 3: Hierarchical clustering of top 10-ranked hypoxia-response genes significantly associated with TS, showing gene expression variation among patients. The heat map represents relative intensity values of gene expression levels. Supplementary Figure 4: Hierarchical clustering of top 10-ranked hypoxia-response genes significantly associated with OS, showing gene expression variation among patients. The heat map represents relative intensity values of gene expression levels. Supplementary Figure 5: Optimized between-group classification (OBC) sensitivity analysis for angiogenesis-associated signature (A) and hypoxia-response signature predictive of TTP under BE. Supplementary Figure 6: Association between the expression of 10-gene hypoxia-response signature predictive of TTP under BE in our study, and PFS of second line sorafenib-treated patients enrolled in the BATTLE-1 trial,1 GEO accession number: GSE33072;2 P = 0.0186, calculated by log-tank test.
Supplementary Table 1 from Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer
Authors: Fankhauser Matthew , Tan Yuen , Macintyre Geoff , Haviv Izhak , Hong Matthew K.H. , Nguyen Anne , Pedersen John S. , Costello Anthony J. , Hovens Christopher M. , Corcoran Niall M.
Published: April 2023

PDF file - 6KB, Table S1. List of genes used for geneset enrichment analysis.
Supplementary Table 1 from EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Authors: Kobayashi Yoshihisa , Togashi Yosuke , Yatabe Yasushi , Mizuuchi Hiroshi , Jangchul Park , Kondo Chiaki , Shimoji Masaki , Sato Katsuaki , Suda Kenichi , Tomizawa Kenji , Takemoto Toshiki , Hida Toyoaki , Nishio Kazuto , Mitsudomi Tetsuya
Published: April 2023

Supplementary Table 1. Individual data on the clinical response of lung cancers harboring E709K/A or G719A/S to gefitinib or erlotinib.
Supplementary Table S2 from Recurrent PRDM10 Gene Fusions in Undifferentiated Pleomorphic Sarcoma
Authors: Hofvander Jakob , Tayebwa Johnbosco , Nilsson Jenny , Magnusson Linda , Brosjö Otte , Larsson Olle , Vult von Steyern Fredrik , Mandahl Nils , Fletcher Christopher D.M. , Mertens Fredrik
Published: April 2023

Supplementary Table S2. Primers used for RT-PCR and sequencing
Supplementary Figure S1 from Recurrent PRDM10 Gene Fusions in Undifferentiated Pleomorphic Sarcoma
Authors: Hofvander Jakob , Tayebwa Johnbosco , Nilsson Jenny , Magnusson Linda , Brosjö Otte , Larsson Olle , Vult von Steyern Fredrik , Mandahl Nils , Fletcher Christopher D.M. , Mertens Fredrik
Published: April 2023

Supplementary Figure S1. qRT-PCR results for PRDM10
Supplementary Figure 1 Legend from Recurrent PRDM10 Gene Fusions in Undifferentiated Pleomorphic Sarcoma
Authors: Hofvander Jakob , Tayebwa Johnbosco , Nilsson Jenny , Magnusson Linda , Brosjö Otte , Larsson Olle , Vult von Steyern Fredrik , Mandahl Nils , Fletcher Christopher D.M. , Mertens Fredrik
Published: April 2023

Supplementary Figure 1 Legend.
Supplementary Appendix from A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma
Authors: Gómez Soledad , Garrido-Garcia Alícia , Garcia-Gerique Laura , Lemos Isadora , Suñol Mariona , de Torres Carmen , Kulis Marta , Pérez-Jaume Sara , Carcaboso Ángel M. , Luu Betty , Kieran Mark W. , Jabado Nada , Kozlenkov Alexey , Dracheva Stella , Ramaswamy Vijay , Hovestadt Volker , Johann Pascal , Jones David T.W. , Pfister Stefan M. , Morales La Madrid Andrés , Cruz Ofelia , Taylor Michael D. , Martin-Subero Jose-Ignacio , Mora Jaume , Lavarino Cinzia
Published: April 2023

Supplementary Methods Supplementary Figure 1 Unsupervised DNA methylation analysis of the training cohort. Supplementary Figure 2 Comparison between the Illumina Infinium Human Methylation450K BeadChip and the Methylation EPIC BeadChip 850K array platforms. Supplementary Figure 3 Specificity of the epigenetic biomarkers for medulloblastoma subgroups. Supplementary Figure 4 Assay performance for low-input titration series. Supplementary Figure 5 Validation of the epigenetic classifier Panel EpiWNT-SHH using DNA methylation microarray data of medulloblastoma samples. Supplementary Figure 6 Validation of the methylation pattern of Panel EpiWNT-SHH using pyrosequencing and direct bisulfite sequencing. Supplementary Figure 7 Schematic overview of the experimental strategy applied for identification of the epigenetic biomarkers and the development of the classifier EpiG3-G4. Supplementary Figure 8 Validation of the epigenetic classifier Panel EpiG3-G4 using DNA methylation microarray data.
Supplementary Figure S2 from Autocrine Activation of CHRM3 Promotes Prostate Cancer Growth and Castration Resistance via CaM/CaMKK–Mediated Phosphorylation of Akt
Authors: Wang Naitao , Yao Ming , Xu Jin , Quan Yizhou , Zhang Kaiqing , Yang Ru , Gao Wei-Qiang
Published: April 2023

Supplementary Figure S2. Autocrine activation of CHRM3 promotes cell migration in scratch test.
Supplementary Figure 2 from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ
Authors: Soong Ruey-Shyang , Song Liwen , Trieu Janson , Knoff Jayne , He Liangmei , Tsai Ya-Chea , Huh Warner , Chang Yung-Nien , Cheng Wen-Fang , Roden Richard B.S. , Wu T.-C. , Trimble Cornelia L. , Hung Chien-Fu
Published: April 2023

PDF file - 81K, Characterization of tumor infiltrating T cells following treatment with systemic DNA vaccination and locally applied imiquimod.
Supplementary Figure S1 from Autocrine Activation of CHRM3 Promotes Prostate Cancer Growth and Castration Resistance via CaM/CaMKK–Mediated Phosphorylation of Akt
Authors: Wang Naitao , Yao Ming , Xu Jin , Quan Yizhou , Zhang Kaiqing , Yang Ru , Gao Wei-Qiang
Published: April 2023

Supplementary Figure S1. Analysis of gene expression in Oncomine database and GEO Profiles database.
Supplemental Figure 2 from Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ
Authors: Soong Ruey-Shyang , Song Liwen , Trieu Janson , Knoff Jayne , He Liangmei , Tsai Ya-Chea , Huh Warner , Chang Yung-Nien , Cheng Wen-Fang , Roden Richard B.S. , Wu T.-C. , Trimble Cornelia L. , Hung Chien-Fu
Published: April 2023

Supplemental Figure 2. Characterization of tumor infiltrating T cells following treatment with systemic DNA vaccination and locally applied imiquimod
Supplementary Video 3 from Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer
Authors: Wen Yunfei , Graybill Whitney S. , Previs Rebecca A. , Hu Wei , Ivan Cristina , Mangala Lingegowda S. , Zand Behrouz , Nick Alpa M. , Jennings Nicholas B. , Dalton Heather J. , Sehgal Vasudha , Ram Prahlad , Lee Ju-Seog , Vivas-Mejia Pablo E. , Coleman Robert L. , Sood Anil K.
Published: April 2023

Supplementary Video 3. 3-D SKOV3ip1 spheroids expressing pGFP-LC3 only were treated with MORAB-003